NCT02981342 is a Phase 2 clinical trial of Abemaciclib in Pancreatic Ductal Adenocarcinoma, sponsored by Eli Lilly and Company.

Who is sponsoring NCT02981342?

NCT02981342 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT02981342?

Interventions in NCT02981342: Abemaciclib, LY3023414, Gemcitabine, Capecitabine.

What condition does NCT02981342 study?

NCT02981342 studies Pancreatic Ductal Adenocarcinoma.

Is NCT02981342 still recruiting?

NCT02981342 is currently completed. Last updated 20 November 2019.

Are results published for NCT02981342?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-11-20 · How we verify

NCT02981342

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

Completed Phase 2 Results posted Last updated 20 November 2019

What this trial tests

Phase 2 trial testing Abemaciclib in Pancreatic Ductal Adenocarcinoma in 106 participants. Completed in 9 November 2018.

Timeline

12 January 2017

Primary endpoint
20 April 2018

9 November 2018

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	106
Start date	12 January 2017
Primary completion	20 April 2018
Estimated completion	9 November 2018
Sites	32 locations across France, Belgium, Taiwan, United Kingdom, Israel, Australia, United States, Spain

Drugs / interventions tested

Abemaciclib (abemaciclib) — full drug profile →
LY3023414 — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Capecitabine (capecitabine) — full drug profile →

Conditions studied

Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

18 and older, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) Primary · Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)

Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progres

Group	Value	95% CI
200mg Abemaciclib	15.2	2.9 – 27.4
150mg Abemaciclib + 150mg LY3023414	12.1	1.0 – 23.3
Gemcitabine or Capecitabine	36.4	20 – 52.8

Stage 2: Progression Free Survival (PFS) Primary · Baseline to Measured Progressive Disease or Death Due to Any Cause (Up to 6 Months)

PFS was defined as the time from the date of randomization until first observation of objective progressive disease as defined by RECIST v1.1 or death from any cause, whichever comes first. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a patient does not have a complete baseline disease assessment, then the PFS time will be censored at the randomization date, regardless of whether or no

Group	Value	95% CI
200mg Abemaciclib	1.68	1.35 – 1.84
150mg Abemaciclib + 150mg LY3023414	1.81	1.28 – 1.91
Gemcitabine or Capecitabine	3.25	1.05 – 5.65

Stage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR Secondary · Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Up to 6 Months)

Objective response rate (ORR) is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Group	Value	95% CI
200mg Abemaciclib	3	0 – 8.9
150mg Abemaciclib + 150mg LY3023414	0	NA – NA
Gemcitabine or Capecitabine	3	0 – 8.9

Stage 1: Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib and Its Metabolites (LSN2839567 (M2), LSN3106726 (M20)) Secondary · Cycle(C)1 Day(D)14: 0 hour(h),0.5h,1h,2h,4h,6h,8h post dose

Mean steady state exposure was reported as measured by maximum observed plasma concentration (Cmax).

Abemaciclib

Group	Value	95% CI
150mg Abemaciclib + 150mg Galunisertib	356	± 137

LSN2839567 (M2)

Group	Value	95% CI
150mg Abemaciclib + 150mg Galunisertib	85.1	± 66

LSN3106726 (M20)

Group	Value	95% CI
150mg Abemaciclib + 150mg Galunisertib	153	± 58

Stage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months Secondary · Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 6 Months)

Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD ≥6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defi

Group	Value	95% CI
200mg Abemaciclib	3	0 – 8.9
150mg Abemaciclib + 150mg LY3023414	0	0 – 0
Gemcitabine or Capecitabine	3	0 – 8.9

Stage 2: Overall Survival (OS) Secondary · Baseline to Death from Any Cause (Up to 10 Months)

OS duration is measured from the date of randomization to the date of death from any cause. for participants who is not known to have died as of the data-inclusion cutoff date, OS was censored at the last known alive date. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

Group	Value	95% CI
200mg Abemaciclib	2.71	1.97 – 5.36
150mg Abemaciclib + 150mg LY3023414	3.29	1.97 – 5.03
Gemcitabine or Capecitabine	NA	2.53 – NA

Stage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level Secondary · Baseline, 6 Months

No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.

Group	Value	95% CI
200mg Abemaciclib	4281.53	± 8177.89
150mg Abemaciclib + 150mg LY3023414	3225.29	± 5730.25
Gemcitabine or Capecitabine	-501.17	± 7198.70

Stage 2: Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf) Secondary · Baseline, 6 Months

mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, and enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completel

Pain at its Worst in Last 24 hours

Group	Value	95% CI
200mg Abemaciclib	0.63	± 0.47
150mg Abemaciclib + 150mg LY3023414	-0.33	± 0.55
Gemcitabine or Capecitabine	-0.02	± 0.57

Pain at its Least in Last 24 hours

Group	Value	95% CI
200mg Abemaciclib	0.86	± 0.42
150mg Abemaciclib + 150mg LY3023414	0.18	± 0.49
Gemcitabine or Capecitabine	0.39	± 0.51

Pain on the Average

Group	Value	95% CI
200mg Abemaciclib	0.62	± 0.45
150mg Abemaciclib + 150mg LY3023414	-0.03	± 0.51
Gemcitabine or Capecitabine	-0.07	± 0.53

Pain Right Now

Group	Value	95% CI
200mg Abemaciclib	0.38	± 0.34
150mg Abemaciclib + 150mg LY3023414	0.34	± 0.59
Gemcitabine or Capecitabine	-0.38	± 0.61

Pain Interfered General Activity

Group	Value	95% CI
200mg Abemaciclib	0.64	± 0.47
150mg Abemaciclib + 150mg LY3023414	0.07	± 0.55
Gemcitabine or Capecitabine	0.22	± 0.57

Pain Interfered with Mood

Group	Value	95% CI
200mg Abemaciclib	0.54	± 0.41
150mg Abemaciclib + 150mg LY3023414	0.28	± 0.48
Gemcitabine or Capecitabine	0.60	± 0.50

Pain Interfered Walking Ability

Group	Value	95% CI
200mg Abemaciclib	0.05	± 0.55
150mg Abemaciclib + 150mg LY3023414	0.83	± 0.64
Gemcitabine or Capecitabine	0.19	± 0.67

Pain Interfered with Normal Work

Group	Value	95% CI
200mg Abemaciclib	1.07	± 0.51
150mg Abemaciclib + 150mg LY3023414	0.66	± 0.59
Gemcitabine or Capecitabine	0.19	± 0.61

Stage 2: Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Secondary · Baseline, 6 Months

The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at

Global Health Status

Group	Value	95% CI
200mg Abemaciclib	-6.21	± 3.87
150mg Abemaciclib + 150mg LY3023414	-4.82	± 4.50
Gemcitabine or Capecitabine	-2.40	± 4.64

Functional Scales: Physical Functioning

Group	Value	95% CI
200mg Abemaciclib	-14.44	± 4.40
150mg Abemaciclib + 150mg LY3023414	-11.65	± 5.12
Gemcitabine or Capecitabine	-5.42	± 5.12

Functional Scales: Role Functioning

Group	Value	95% CI
200mg Abemaciclib	-17.09	± 6.17
150mg Abemaciclib + 150mg LY3023414	-18.05	± 7.32
Gemcitabine or Capecitabine	-17.10	± 7.36

Functional Scales: Emotional Functioning

Group	Value	95% CI
200mg Abemaciclib	-4.89	± 4.49
150mg Abemaciclib + 150mg LY3023414	-0.63	± 5.22
Gemcitabine or Capecitabine	2.06	± 5.41

Functional Scales: Cognitive Functioning

Group	Value	95% CI
200mg Abemaciclib	-10.43	± 4.10
150mg Abemaciclib + 150mg LY3023414	-8.39	± 4.77
Gemcitabine or Capecitabine	-5.18	± 4.95

Functional Scale: Social Functioning

Group	Value	95% CI
200mg Abemaciclib	-21.12	± 4.90
150mg Abemaciclib + 150mg LY3023414	-17.09	± 5.72
Gemcitabine or Capecitabine	-2.00	± 5.95

Symptom Scales: Fatigue

Group	Value	95% CI
200mg Abemaciclib	14.13	± 4.92
150mg Abemaciclib + 150mg LY3023414	14.90	± 5.73
Gemcitabine or Capecitabine	5.64	± 5.71

Symptom Scales: Nausea and Vomiting

Group	Value	95% CI
200mg Abemaciclib	7.98	± 5.57
150mg Abemaciclib + 150mg LY3023414	9.42	± 6.47
Gemcitabine or Capecitabine	11.88	± 6.50

Stage 1: PK: Steady State Trough Pre Dose Concentration of LY3023414 Secondary · C2D1: 0h, C3D1: 0h, C4D1: 0h

Mean steady state exposure was reported by trough pre-dose plasma concentrations.

Group	Value	95% CI
150mg Abemaciclib + 150mg LY3023414	27.3	± 450

Stage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose Secondary · C1D1: 2h Post dose

Mean single dose exposure was reported by plasma concentrations collected approximately 2 hours post-dose.

Group	Value	95% CI
150mg Abemaciclib + 150mg LY3023414	518	± 67

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 30 weeks. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

150mg Abemaciclib + 150mg Galunisertib (Safety Lead - In)

Serious: 4/7 (57%)

Deaths: 5/7

200mg Abemaciclib

Serious: 17/32 (53%)

Deaths: 22/32

150mg Abemaciclib + 150mg LY3023414

Serious: 18/33 (55%)

Deaths: 21/33

Gemcitabine or Capecitabine

Serious: 15/26 (58%)

Deaths: 12/26

Serious adverse events (62 terms)

Reaction	System	150mg Abemaciclib + 150mg …	200mg Abemaciclib	150mg Abemaciclib + 150mg …	Gemcitabine or Capecitabine
Vomiting	Gastrointestinal disorders	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—
Pyrexia	General disorders	—	—	—	—
Bile duct obstruction	Hepatobiliary disorders	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—
Ascites	Gastrointestinal disorders	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—
Duodenal stenosis	Gastrointestinal disorders	—	—	—	—
Gastric ulcer haemorrhage	Gastrointestinal disorders	—	—	—	—
Gastrointestinal perforation	Gastrointestinal disorders	—	—	—	—
Intestinal obstruction	Gastrointestinal disorders	—	—	—	—
Large intestinal obstruction	Gastrointestinal disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Obstruction gastric	Gastrointestinal disorders	—	—	—	—
Oesophagitis	Gastrointestinal disorders	—	—	—	—
Subileus	Gastrointestinal disorders	—	—	—	—
Asthenia	General disorders	—	—	—	—
Chills	General disorders	—	—	—	—
Fatigue	General disorders	—	—	—	—
General physical health deterioration	General disorders	—	—	—	—

Other adverse events (104 terms — click to expand)

Reaction	System	150mg Abemaciclib + 150mg …	200mg Abemaciclib	150mg Abemaciclib + 150mg …	Gemcitabine or Capecitabine
Diarrhoea	Gastrointestinal disorders	—	—	—	—
Fatigue	General disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—
Palmar-plantar erythrodysaesthesia syndrome	Skin and subcutaneous tissue disorders	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—
Pyrexia	General disorders	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—
Ascites	Gastrointestinal disorders	—	—	—	—
Asthenia	General disorders	—	—	—	—
Bile duct obstruction	Hepatobiliary disorders	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—
White blood cell count decreased	Investigations	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—
Dysgeusia	Nervous system disorders	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—
General physical health deterioration	General disorders	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—
Weight decreased	Investigations	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—
Confusional state	Psychiatric disorders	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—	—	—

Most-reported serious reactions: Vomiting, Thrombocytopenia, Abdominal pain, Stomatitis, Pyrexia, Bile duct obstruction, Pulmonary embolism, Anaemia.

Data from ClinicalTrials.gov NCT02981342 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J, Nie J, Ma X, Wei Y, et al · · 2019 · cited 1142× · PMID 30782187 · DOI 10.1186/s12943-019-0954-x
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.
Jiang N, Dai Q, Su X, Fu J, et al · · 2020 · cited 419× · PMID 32333246 · DOI 10.1007/s11033-020-05435-1
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
Klein ME, Kovatcheva M, Davis LE, Tap WD, et al · · 2018 · cited 308× · PMID 29731395 · DOI 10.1016/j.ccell.2018.03.023
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y, Gong Y, Fan Z, Luo G, et al · · 2020 · cited 231× · PMID 33008426 · DOI 10.1186/s13045-020-00958-3
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG. · · 2019 · cited 148× · PMID 30931508 · DOI 10.1186/s40169-019-0226-9
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM, Waters AM, Klomp JE, Javaid S, et al · · 2023 · cited 125× · PMID 36346366 · DOI 10.1158/0008-5472.can-22-0391
TAMing pancreatic cancer: combat with a double edged sword.
Lankadasari MB, Mukhopadhyay P, Mohammed S, Harikumar KB. · · 2019 · cited 84× · PMID 30925924 · DOI 10.1186/s12943-019-0966-6
Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges.
Poh AR, Ernst M. · · 2021 · cited 79× · PMID 34201127 · DOI 10.3390/cancers13122860

Verify or expand the search:

Other trials of Abemaciclib

Trials testing the same drug.

NCT07492641 — BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT07428018 — Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Onco · Phase 2 · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT06498648 — Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tis · Phase 1, PHASE2 · recruiting
NCT07441369 — Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer · Phase 2 · enrolling by invitation

Other recruiting trials for Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

NCT07324096 — A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve · NA · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
NCT07232810 — Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer · NA · recruiting
NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02981342 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 20 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02981342.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing